Lymphangioleiomyomatosis (LAM) - Pipeline Insight, 2020
This report can be delivered to the clients within 24-48 Hours
DelveInsight’s, “Lymphangioleiomyomatosis– Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lymphangioleiomyomatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lymphangioleiomyomatosis: Overview
Lymphangioleiomyomatosis (LAM) also known as lymphangiomyomatosis is a condition that affects the lungs, the kidneys, and the lymphatic system. The lymphatic system consists of a network of vessels that transport lymph fluid and immune cells throughout the body. Lymph fluid helps exchange immune cells, proteins, and other substances between the blood and tissues. LAM is found almost exclusively in women. It often occurs as a feature of an inherited syndrome called tuberous sclerosis complex. When LAM occurs alone it is called isolated or sporadic LAM.
Symptoms
Signs and symptoms of LAM most often appear during a woman's thirties. Affected women have an overgrowth of abnormal smooth muscle-like cells (LAM cells) in the lungs, resulting in the formation of lung cysts and the destruction of normal lung tissue. They may also have an accumulation of fluid in the cavity around the lungs (chylothorax). The lung abnormalities resulting from LAM may cause difficulty breathing (dyspnea), chest pain, and coughing, which may bring up blood (hemoptysis). Many women with this disorder have recurrent episodes of collapsed lung (spontaneous pneumothorax).
Diagnosis
Routine investigations can be supportive but not diagnostic in LAM. The chest radiograph often appears normal in early disease, although may show a pneumothorax or pleural effusion. The most common abnormalities are reticulonodular shadowing and cysts or bullae. The lung volumes are generally preserved and the combination of preserved lung volumes and interstitial changes occurs in a small number of conditions including LAM, Langerhans' cell histiocytosis, sarcoidosis and chronic hypersensitivity pneumonitis.
Treatment
Standard treatment of lymphangioleiomyomatosis is lung transplantation, but the disorder can recur in transplanted lungs. Rapamune (sirolimus) has been approved to treat lymphangioleiomyomatosis (LAM), a rare progressive lung disease that primarily affects women of childbearing age. Rapamune is manufactured by Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc. Treatment with sirolimus is recommended for patients with abnormal or declining lung function. Alternative treatments, such as hormonal manipulation with progestins, tamoxifen, and oophorectomy, are largely ineffective and not recommended.
Lymphangioleiomyomatosis Emerging Drugs Chapters
This segment of the Lymphangioleiomyomatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lymphangioleiomyomatosis Emerging Drugs
Further product details are provided in the report……..
Lymphangioleiomyomatosis: Therapeutic Assessment
This segment of the report provides insights about the different Lymphangioleiomyomatosis drugs segregated based on following parameters that define the scope of the report, such as:
Lymphangioleiomyomatosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I and preclinical stage. It also analyses Lymphangioleiomyomatosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphangioleiomyomatosis drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Lymphangioleiomyomatosis– Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lymphangioleiomyomatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Lymphangioleiomyomatosis: Overview
Lymphangioleiomyomatosis (LAM) also known as lymphangiomyomatosis is a condition that affects the lungs, the kidneys, and the lymphatic system. The lymphatic system consists of a network of vessels that transport lymph fluid and immune cells throughout the body. Lymph fluid helps exchange immune cells, proteins, and other substances between the blood and tissues. LAM is found almost exclusively in women. It often occurs as a feature of an inherited syndrome called tuberous sclerosis complex. When LAM occurs alone it is called isolated or sporadic LAM.
Symptoms
Signs and symptoms of LAM most often appear during a woman's thirties. Affected women have an overgrowth of abnormal smooth muscle-like cells (LAM cells) in the lungs, resulting in the formation of lung cysts and the destruction of normal lung tissue. They may also have an accumulation of fluid in the cavity around the lungs (chylothorax). The lung abnormalities resulting from LAM may cause difficulty breathing (dyspnea), chest pain, and coughing, which may bring up blood (hemoptysis). Many women with this disorder have recurrent episodes of collapsed lung (spontaneous pneumothorax).
Diagnosis
Routine investigations can be supportive but not diagnostic in LAM. The chest radiograph often appears normal in early disease, although may show a pneumothorax or pleural effusion. The most common abnormalities are reticulonodular shadowing and cysts or bullae. The lung volumes are generally preserved and the combination of preserved lung volumes and interstitial changes occurs in a small number of conditions including LAM, Langerhans' cell histiocytosis, sarcoidosis and chronic hypersensitivity pneumonitis.
Treatment
Standard treatment of lymphangioleiomyomatosis is lung transplantation, but the disorder can recur in transplanted lungs. Rapamune (sirolimus) has been approved to treat lymphangioleiomyomatosis (LAM), a rare progressive lung disease that primarily affects women of childbearing age. Rapamune is manufactured by Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc. Treatment with sirolimus is recommended for patients with abnormal or declining lung function. Alternative treatments, such as hormonal manipulation with progestins, tamoxifen, and oophorectomy, are largely ineffective and not recommended.
Lymphangioleiomyomatosis Emerging Drugs Chapters
This segment of the Lymphangioleiomyomatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lymphangioleiomyomatosis Emerging Drugs
- Rapamycin- AI Therapeutics
- Saracatinib: AstraZeneca
Further product details are provided in the report……..
Lymphangioleiomyomatosis: Therapeutic Assessment
This segment of the report provides insights about the different Lymphangioleiomyomatosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Lymphangioleiomyomatosis
- Phases
- Late stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II and
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intravenous
- Intravesical
- Oral etc.
- Molecule Type
- Antineoplastics
- Vaccine
- Gene therapies
- Immunotherapy
- Metal
- Monoclonal antibodies
- Nanoparticle
- Oncolytic viruses
- Peptide
- Plasmid
- Protein
- Small molecule
- Ligand
- Bacteria and others.
- Product Type
Lymphangioleiomyomatosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I and preclinical stage. It also analyses Lymphangioleiomyomatosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphangioleiomyomatosis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lymphangioleiomyomatosis R&D. The therapies under development are focused on novel approaches to treat/improve Lymphangioleiomyomatosis.
- Lymphangioleiomyomatosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lymphangioleiomyomatosis drugs?
- How many Lymphangioleiomyomatosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lymphangioleiomyomatosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lymphangioleiomyomatosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lymphangioleiomyomatosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- AI Therapeutics
- AstraZeneca
- Rapamycin
- Saracatinib
Introduction
Executive Summary
Lymphangioleiomyomatosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lymphangioleiomyomatosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lymphangioleiomyomatosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lymphangioleiomyomatosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products
Comparative Analysis
Rapamycin- AI Therapeutics
Product Description
Research and Development
Product Development Activities
Saracatinib: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix
Executive Summary
Lymphangioleiomyomatosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lymphangioleiomyomatosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lymphangioleiomyomatosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lymphangioleiomyomatosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products
Comparative Analysis
Rapamycin- AI Therapeutics
Product Description
Research and Development
Product Development Activities
Saracatinib: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Non Muscle Invasive Bladder Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Non Muscle Invasive Bladder Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Non Muscle Invasive Bladder Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Non Muscle Invasive Bladder Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products